Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Palantir Technologies Inc (PLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Palantir Technologies Inc — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Palantir Technologies Inc trades at $197.95 (market cap $501.45B). The key difference: Palantir Technologies Inc is far larger — about 515.4× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Palantir Technologies Inc is trading nearer its 52-week high, Maravai LifeSciences Holdings Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Palantir Technologies Inc for 79 Days on average.
| MRVI | PLTR | |
|---|---|---|
Market Cap | $972.90M | $501.45B |
Volume | 4,325,710 | 18,438,992 |
Sector | Health | Technology |
52-Week High | $9.00 | $209.05 |
52-Week Low | $2.83 | $107.27 |
Typical Hold Time | 0 Days | 79 Days |
Enterprise Value | $1.08B | $492.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Palantir (PLTR) trades at $200.97, down 3.84% on the day but maintains strong bullish technical momentum with consecutive earnings beats. The company demonstrates exceptional fundamental performance with 56.2% revenue growth in 2025, reaching $4.48 billion, and net income margin expanding to 36.3%. Recent partnership with Armada for sovereign AI infrastructure and consistent analyst optimism highlight the stock's growth trajectory despite premium valuation metrics.
Outlook remains positive with accelerating AI adoption driving growth, though elevated P/E of 178.35 presents valuation risk. Wall Street consensus targets $195.86 with 54% buy ratings, while technical indicators show potential resistance near $213-$219 levels. Key risks include growth normalization and competitive pressures in the expanding AI software market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →
